ViroGates A/S
The answer first
Does ViroGates beat the market?
No, ViroGates has not beaten the market over the last year.
The ranking · Quality, value and trend combined
Better than 11% of Nordic stocks
- Quality67
- Value5
- Trend14
No. 162 of 195 in healthcare
Max for seven days
Follow ViroGates with AuroraAurora lets you know at the next report. No card.
Both with dividends. Figures as of 19 November 2026. General analysis, not personal advice.
Follow your thesis
Ask Aurora about ViroGates
Your first answer is free, no account needed.
Do you own ViroGates, or are you thinking about it?
See it next to the rest of your portfolio, or build your first one with ViroGates and a few more. Free, no card.
Super Stock+46.4%In short
- ViroGates has fallen 48.0% over the past year, including dividends.
- Overall, ViroGates ranks better than 11% of Nordic stocks on quality, value and trend.
- The largest fall over the past three years was 97.0%. The price is 96.1% below its peak now.
Who owns ViroGates? See the major shareholders and their stakes
Quality, value and trend
Quality is about the company, value about the price you pay, and trend about the share price. Each pillar shows the numbers it is built on.
Quality, value and trend together. Better than 11% of Nordic stocks.
No. 162 of 195 in healthcare
Medium An average company: the accounts are neither especially strong nor weak.
No. 92 of 196 in healthcareTypical in healthcare: 64Typical in the Nordics: 50
- Debt to equityBorrowings divided by equity0.27
- Asset turnoverSales divided by everything the company owns0.42
- Return on equityProfit divided by equity−59.1%
- Cash conversionOperating cash flow divided by profit–
The ranking is built on equity ratio, ROA and how steadily profit grows.
Low High price: buyers pay a lot today, often because they expect growth.
No. 161 of 197 in healthcareTypical in healthcare: 20Typical in the Nordics: 50
- P/BPrice divided by equity4.7
- P/SPrice divided by sales8.0
- P/EPrice divided by earningsnegative earnings
- P/CFPrice divided by operating cash flownegative earnings
The ranking is built on P/E, P/B and P/S.
Low Headwind in the share price: it has done worse than most over the last year.
No. 147 of 198 in healthcareTypical in healthcare: 34Typical in the Nordics: 50
- 3 months−34.9%
- 6 months−32.4%
- 9 months−43.4%
- 12 months−48.0%
The ranking is built on 3, 6 and 12–1 months.
Return and risk
Return with dividends reinvested.
The funds that own ViroGates
4 funds we follow own ViroGates. The share is how much of the fund the stock makes up.
- Denmark4
From the funds' latest known holdings.
About ViroGates
ViroGates A/S is a company in healthcare, listed on Nasdaq Copenhagen. By market value, ViroGates is number 17 of 20 companies in healthcare on Nasdaq Copenhagen. ViroGates has not paid a dividend in the past twelve months. Of the three measures in the ranking, ViroGates is strongest on quality, better than 67% of Nordic stocks. The share trades in DKK. It has around 7 employees.
ViroGates A/S, an in vitro diagnostics company, develops and sells blood tests for measuring chronic inflammation for the healthcare sector. It offers suPARnostic TurbiLatex, a CE-IVD approved particle-enhanced turbidimetric immunoassay for quantitative measurement of suPAR in human plasma; suPARnostic AUTO Flex ELISA kit, a fully quantitative immunoassay designed for accurate and reliable measurement of soluble urokinase plasminogen activator receptor in human plasma; and suPARnostic Quick Triage, a test for rapid, quantitative measurement of suPAR levels. ViroGates A/S was founded in 2000 and is headquartered in Birkerød, Denmark.


See the full analysis of ViroGates.
The accounts, dividends, 40 years of charts and the comparison with other stocks are in the app.
Free forever · No card